Suchergebnisse - "Yokoyama, Keitaro"

PubPharm (28)

1

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis : Pharmacokinetic and Pharmacodynamic Properties

enthalten in: Clinical pharmacokinetics | 2022

von Kazama, J. | Koiwa, F. | Yokoyama, K. | +4

2

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism : results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2021

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

3

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism

enthalten in: Nephrology (Carlton, Vic.) | 2020

von Shigematsu, T. | Fukagawa, M. | Yokoyama, K. | +4

4

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level : an analysis from the MBD-5D study

enthalten in: Clinical and experimental nephrology | 2020

von Asada, S. | Yokoyama, K. | Miyakoshi, C. | +8

5

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis : The J-DAVID Randomized Clinical Trial

enthalten in: JAMA | 2018

von J-DAVID Investigators | Shoji, T. | Inaba, M. | +59

CommentIn: JAMA. 2018 Dec 11;320(22):2319-2321. - PMID 30535205

6

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

enthalten in: Clinical and experimental nephrology | 2018

von Shigematsu, T. | Fukagawa, M. | Yokoyama, K. | +46

7

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2017

von Fukagawa, M. | Yokoyama, K. | Shigematsu, T. | +6

8

Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia : An Open-Label, Multicenter, Phase III Study

enthalten in: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation | 2017

von Koiwa, F. | Yokoyama, K. | Fukagawa, M. | +1

9

A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients 

enthalten in: Clinical nephrology | 2017

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +4

10

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia : A randomized, open-label, multicentre, 12-week phase III study

enthalten in: Nephrology (Carlton, Vic.) | 2017

von Koiwa, F. | Yokoyama, K. | Fukagawa, M. | +2